Current Perspectives on the Management of Infantile Atopic Dermatitis

References

• Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125–138. doi:doi:10.1016/s0091-6749(99)70536-19893196
   PubMed Web of Science ®Google Scholar
• Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–8.e23. doi:doi:10.1016/j.jaci.2009.10.00920004783
   PubMed Web of Science ®Google Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of dermatology association and the society for investigative dermatology. J Am Acad Dermatol. 2006;55(3):490–500. doi:doi:10.1016/j.jaad.2006.05.04816908356
   PubMed Web of Science ®Google Scholar
• CPI Inflation Calculator. U.S. Bureau of labor statistics. Available from: https://www.bls.gov/data/inflation_calculator.htm. Accessed 831, 2020
   Google Scholar
• Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys [published correction appears in Lancet. 2007 Sep 29;370(9593):1128]. Lancet. 2006;368(9537):733–743. doi:doi:10.1016/S0140-6736(06)69283-016935684
   PubMed Web of Science ®Google Scholar
• Williams H, Stewart A, von Mutius E, Cookson W, Anderson HR. International Study of Asthma and Allergies in Childhood (ISAAC) phase one and three study groups. Is eczema really on the increase worldwide? J Allergy Clin Immunol. 2008;121(4):947–54.e15. doi:doi:10.1016/j.jaci.2007.11.00418155278
   PubMed Web of Science ®Google Scholar
• Hanifin J, Rajka G. Diagnostic features of atopic-dermatitis. Acta Derm Venereol. 1980;92:44–47.
   Google Scholar
• Williams HC, Burney PG, Hay RJ, et al. The U.K. working party’s diagnostic criteria for atopic dermatitis. i. derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383–396. doi:doi:10.1111/j.1365-2133.1994.tb08530.x7918015
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Chopra R, Silverberg JI. Systematic review of diagnostic criteria used in atopic dermatitis randomized controlled trials. Am J Clin Dermatol. 2018;19(1):15–22. doi:doi:10.1007/s40257-017-0299-4
   Web of Science ®Google Scholar
• Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. doi:doi:10.1016/j.jaad.2018.09.03530287309
   PubMed Web of Science ®Google Scholar
• Schmitt J, Langan S, Williams HC. European dermato-epidemiology network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007;120(6):1389–1398. doi:doi:10.1016/j.jaci.2007.08.01117910890
   PubMed Web of Science ®Google Scholar
• Tackett KJ, Jenkins F, Morrell DS, McShane DB, Burkhart CN. Structural racism and its influence on the severity of atopic dermatitis in African American children. Pediatr Dermatol. 2020;37(1):142–146. doi:doi:10.1111/pde.1405831854003
   PubMed Web of Science ®Google Scholar
• Hill DA, Spergel JM. The atopic march: critical evidence and clinical relevance [published correction appears in Ann Allergy Asthma Immunol. 2018 Mar 9]. Ann Allergy Asthma Immunol. 2018;120(2):131–137. doi:doi:10.1016/j.anai.2017.10.03729413336
   PubMed Web of Science ®Google Scholar
• Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6 Suppl):S118–S127. doi:doi:10.1016/j.jaci.2003.09.03314657842
   PubMed Web of Science ®Google Scholar
• Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol. 1994;30(1):35–39. doi:doi:10.1016/s0190-9622(94)70004-48277028
   PubMed Web of Science ®Google Scholar
• Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925–931. doi:doi:10.1016/j.jaci.2004.01.77815131576
   PubMed Web of Science ®Google Scholar
• Vakili V, Mollazade Z, Ahanchian H, Kiafar B, Pedram A. The impact of infantile atopic dermatitis on patients’ and their families’ quality of life. International j Pediatrics. 2019;7(6):9517–9524. doi:doi:10.22038/ijp.2019.37437.3256
   Web of Science ®Google Scholar
• Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159–162. doi:doi:10.1136/adc.76.2.1599068310
   PubMed Web of Science ®Google Scholar
• Tsakok T, Woolf R, Smith CH, Weidinger S, Flohr C. Atopic dermatitis: the skin barrier and beyond. Br J Dermatol. 2019;180(3):464–474. doi:doi:10.1111/bjd.1693429969827
   PubMed Web of Science ®Google Scholar
• Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446. doi:doi:10.1038/ng176716550169
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol. 2013;133(7):1752–1759. doi:doi:10.1038/jid.2013.1923334343
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:doi:10.1038/s41572-018-0001-z29930242
   PubMed Web of Science ®Google Scholar
• Powers CE, McShane DB, Gilligan PH, Burkhart CN, Morrell DS. Microbiome and pediatric atopic dermatitis. J Dermatol. 2015;42(12):1137–1142. doi:doi:10.1111/1346-8138.1307226388516
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:doi:10.1016/j.jaad.2014.03.02324813302
   PubMed Web of Science ®Google Scholar
• van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturizers for eczema: abridged Cochrane systematic review including GRADE assessments. Br J Dermatol. 2017;177(5):1256–1271. doi:doi:10.1111/bjd.1560228432721
   PubMed Web of Science ®Google Scholar
• Skjerven HO, Rehbinder EM, Vettukattil R, et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial [published correction appears in Lancet. 2020 Mar 21;395(10228):e53]. Lancet. 2020;395(10228):951–961. doi:doi:10.1016/S0140-6736(19)32983-632087121
   PubMed Web of Science ®Google Scholar
• Chopra R, Vakharia PP, Sacotte R, Silverberg JI. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017;119(5):435–440. doi:doi:10.1016/j.anai.2017.08.28929150071
   PubMed Web of Science ®Google Scholar
• Sawada Y, Tong Y, Barangi M, et al. Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro [published correction appears in J Allergy Clin Immunol. 2019 Nov;144(5):1456]. J Allergy Clin Immunol. 2019;143(5):1946–1948. doi:doi:10.1016/j.jaci.2019.01.00930677478
   PubMed Web of Science ®Google Scholar
• González-López G, Ceballos-Rodríguez RM, González-López JJ, Feito Rodríguez M, Herranz-Pinto P. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol. 2017;177(3):688–695. doi:doi:10.1111/bjd.1516527861727
   PubMed Web of Science ®Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S50–S58. doi:doi:10.1016/j.jaad.2005.04.03015968264
   PubMed Web of Science ®Google Scholar
• McKenzie AW, Stoughton R. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86(5):608. doi:doi:10.1001/archderm.1962.01590110044005.
   Google Scholar
• Hydrocortisone Butyrate Cream 0.1% (Lipophilic) [Prescribing Information]. Mahwah: Glenmark Generics Inc; 2013.
   Google Scholar
• Desonate^® (Desonide) Gel 0.05% [Prescribing Information]. Whippany: Bayer HealthCare Pharmaceuticals Inc; 2014.
   Google Scholar
• Verdeso^® (Desonide) Foam 0.05% [Prescribing Information]. Research Triangle Park: Stiefel Laboratories, Inc; 2011.
   Google Scholar
• Cutivate^® (Fluticasone Propionate) Cream 0.05% [Prescribing Information]. Melville: Nycomed US Inc; 2010.
   Google Scholar
• Cutivate^® (Fluticasone Propionate) Lotion 0.05% [Prescribing Information]. Melville: Fougera Pharmaceuticals Inc; 2015.
   Google Scholar
• Derma-Smoothe/FS^® (Fluocinolone Acetonide) Topical Oil 0.01% [Prescribing Information]. Sanford: Hill Dermaceuticals, Inc; 2007.
   Google Scholar
• Dermatop^® (Prednicarbate) Emollient Cream 0.1% [Prescribing Information]. Bridgewater: Sanofi-aventis U.S. LLC; 2010.
   Google Scholar
• Aclovate^® (Alclometasone Dipropionate) Cream 0.05% and Ointment 0.05% [Prescribing Information]. Melville: Nycomed US Inc; 2010.
   Google Scholar
• Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415–428. doi:doi:10.1111/j.1365-2133.2010.10030.x20819086
   PubMed Web of Science ®Google Scholar
• Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20(1):59–66. doi:doi:10.1111/j.1399-3038.2008.00735.x18298423
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–18. doi:doi:10.1016/j.jaad.2005.01.01016384751
   PubMed Web of Science ®Google Scholar
• Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol. 1998;138(2):293–296. doi:doi:10.1046/j.1365-2133.1998.02077.x9602877
   PubMed Web of Science ®Google Scholar
• Nelson AA, Miller AD, Fleischer AB, Balkrishnan R, Feldman SR. How much of a topical agent should be prescribed for children of different sizes? J Dermatolog Treat. 2006;17(4):224–228. doi:doi:10.1080/0954663060089499816971317
   PubMed Web of Science ®Google Scholar
• Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD. Evaluation of hypothalamic-pituitary-adrenal axis suppression following cutaneous use of topical corticosteroids in children: a meta-analysis. Horm Res Paediatr. 2018;89(6):389–396. doi:doi:10.1159/00048912529898449
   PubMed Web of Science ®Google Scholar
• Thomas MW, Panter AT, Morrell DS. Corticosteroids’ effect on the height of atopic dermatitis patients: a controlled questionnaire study. Pediatr Dermatol. 2009;26(5):524–528. doi:doi:10.1111/j.1525-1470.2009.00865.x19840305
   PubMed Web of Science ®Google Scholar
• Protopic^® (Tacrolimus) Ointment 0.03% and Ointment 0.1% [Prescribing Information]. Deerfield: Fujisawa Healthcare, Inc; 2000.
   Google Scholar
• Elidel^® (Pimecrolimus) Cream 1% [Prescribing Information]. East Hanover: Novartis Pharmaceuticals Corporation; 2010.
   Google Scholar
• Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150(3):554–562. doi:doi:10.1046/j.1365-2133.2004.05782.x15030341
   PubMed Web of Science ®Google Scholar
• Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi:doi:10.1111/j.1525-1470.2009.00981.x19840309
   PubMed Web of Science ®Google Scholar
• Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 2008;58(6):990–999. doi:doi:10.1016/j.jaad.2008.02.00818359127
   PubMed Web of Science ®Google Scholar
• Paller AS, Eichenfield LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122(6):e1210–e1218. doi:doi:10.1542/peds.2008-134319015204
   PubMed Web of Science ®Google Scholar
• Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010;24(9):1040–1046. doi:doi:10.1111/j.1468-3083.2010.03577.x20158589
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the joint task force practice parameter and american academy of dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–S57. doi:doi:10.1016/j.jaci.2017.01.00928390477
   PubMed Web of Science ®Google Scholar
• El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009;54(2):76–87. doi:doi:10.1016/j.jdermsci.2009.02.00219303745
   PubMed Web of Science ®Google Scholar
• Huang X, Efficacy XB. Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis. Dermatology. 2015;231(1):41–49. doi:doi:10.1159/00038194826043855
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75. doi:doi:10.1186/s12887-016-0607-927267134
   PubMed Web of Science ®Google Scholar
• Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–315. doi:doi:10.1111/pai.1233125557211
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14(3):163–178. doi:doi:10.1007/s40257-013-0020-123703374
   PubMed Web of Science ®Google Scholar
• Castellsague J, Kuiper JG, Pottegård A, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310. doi:doi:10.2147/CLEP.S14644229559812
   PubMed Web of Science ®Google Scholar
• Paller AS, Fölster-Holst R, Chen SC, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020;83(2):375–381. doi:doi:10.1016/j.jaad.2020.03.07532246968
   PubMed Web of Science ®Google Scholar
• Eucrisa^® (Crisaborole) Ointment 2% [Prescribing Information]. New York: Pfizer Inc; 2020.
   Google Scholar
• Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016;33(4):380–387. doi:doi:10.1111/pde.1287227193740
   PubMed Web of Science ®Google Scholar
• Tom WL, Van Syoc M, Chanda S, Zane LT. Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: an Open-Label Phase 2a Study. Pediatr Dermatol. 2016;33(2):150–159. doi:doi:10.1111/pde.1278026777394
   PubMed Web of Science ®Google Scholar
• Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double-blind, vehicle-controlled study in healthy volunteers. Am J Clin Dermatol. 2016;17(5):519–526. doi:doi:10.1007/s40257-016-0204-627335049
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015;14(12):1394–1399.26659931
   PubMed Web of Science ®Google Scholar
• Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14(10):1108–1112.26461821
   PubMed Web of Science ®Google Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults [published correction appears in J Am Acad Dermatol. 2017 Apr;76(4):777]. J Am Acad Dermatol. 2016;75(3):494–503.e6. doi:doi:10.1016/j.jaad.2016.05.04627417017
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641–649.e5. doi:doi:10.1016/j.jaad.2017.06.01028823881
   PubMed Web of Science ®Google Scholar
• Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase iv open-label study (crisade care 1). Am J Clin Dermatol. 2020;21(2):275–284. doi:doi:10.1007/s40257-020-00510-632212104
   PubMed Web of Science ®Google Scholar
• Fahrbach K, Tarpey J, Washington EB, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis [published online ahead of print, 2020 may 20]. Dermatol Ther (Heidelb). 2020. doi:doi:10.1007/s13555-020-00389-5
   Web of Science ®Google Scholar
• Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and UVA phototherapy. J Investig Dermatol Symp Proc. 1999;4(1):70–72. doi:10.1038/sj.jidsp.5640185
   Google Scholar
• Tintle S, Shemer A, Suárez-Fariñas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol. 2011;128(3):583–93.e934. doi:10.1016/j.jaci.2011.05.04221762976
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi:10.1016/j.jaad.2014.03.03024813298
   PubMed Web of Science ®Google Scholar
• Collins P, Ferguson J. Narrowband (TL-01) UVB air-conditioned phototherapy for atopic eczema in children. Br J Dermatol. 1995;133(4):653–655. doi:10.1111/j.1365-2133.1995.tb02725.x7577604
   PubMed Web of Science ®Google Scholar
• Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007;32(1):28–33. doi:10.1111/j.1365-2230.2006.02292.x17305905
   PubMed Web of Science ®Google Scholar
• Pavlovsky M, Baum S, Shpiro D, Pavlovsky L, Pavlotsky F. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? J Eur Acad Dermatol Venereol. 2011;25(6):727–729. doi:10.1111/j.1468-3083.2010.03832.x20726938
   PubMed Web of Science ®Google Scholar
• Darné S, Leech SN, Taylor AE. Narrowband ultraviolet B phototherapy in children with moderate-to-severe eczema: a comparative cohort study. Br J Dermatol. 2014;170(1):150–156. doi:10.1111/bjd.1258023937117
   PubMed Web of Science ®Google Scholar
• Dayal S, Pathak K, Sahu P, Jain VK. Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety. An Bras Dermatol. 2017;92(6):801–806. doi:10.1590/abd1806-4841.2017595829364435
   PubMed Web of Science ®Google Scholar
• Eustace K, Dolman S, Alsharqi A, Sharpe G, Parslew R. Use of Phototherapy in Children. Pediatr Dermatol. 2017;34(2):150–155. doi:10.1111/pde.1307228133819
   PubMed Web of Science ®Google Scholar
• Crall CS, Rork JF, Delano S, Huang JT. Phototherapy in children: considerations and indications. Clin Dermatol. 2016;34(5):633–639. doi:10.1016/j.clindermatol.2016.05.01827638444
   PubMed Web of Science ®Google Scholar
• Juarez MC, Grossberg AL. Phototherapy in the Pediatric Population. Dermatol Clin. 2020;38(1):91–108. doi:10.1016/j.det.2019.08.01231753196
   PubMed Web of Science ®Google Scholar
• Slater NA, Morrell DS. Systemic therapy of childhood atopic dermatitis. Clin Dermatol. 2015;33(3):289–299. doi:10.1016/j.clindermatol.2014.12.00525889129
   PubMed Web of Science ®Google Scholar
• Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: the PeDRA TREAT survey. J Am Acad Dermatol. 2017;76(2):281–285. doi:10.1016/j.jaad.2016.09.02127855965
   PubMed Web of Science ®Google Scholar
• Dupixent^® (Dupilumab) Injection [Prescribing Information]. Tarrytown: Regeneron Pharmaceuticals, Inc; 2020.
   Google Scholar
• Blauvelt A, de Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, Phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi:10.1016/S0140-6736(17)31191-128478972
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi:10.1056/NEJMoa161002027690741
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial [published online ahead of print, 2019 Nov 6]. JAMA Dermatol. 2019;156(1):44–56. doi:10.1001/jamadermatol.2019.3336
   Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Study to investigate the efficacy and safety of dupilumab administered with topical corticosteroids (TCS) in participants ≥6 to <12 years with severe atopic dermatitis (AD). Available from: https://clinicaltrials.gov/ct2/show/NCT03345914?term=NCT03345914&draw=2&rank=1. NLM identifier: NCT03345914 Accessed 712, 2020.
   Google Scholar
• Regeneron Pharmaceuticals. Safety, pharmacokinetics and efficacy of dupilumab in patients ≥6 months to <6 years with moderate-to-severe atopic dermatitis (liberty AD PRESCHOOL) (Liberty AD). Available from: https://clinicaltrials.gov/ct2/show/NCT03346434?term=NCT03346434&draw=2&rank=1. NLM identifier: NCT03346434 Accessed 712, 2020.
   Google Scholar
• Incyte Corporation. TRuE AD1 - an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03745638?term=NCT03745638&draw=2&rank=1. NLM identifier: NCT03745638 Accessed 814, 2020.
   Google Scholar
• Incyte Corporation. TRuE AD2 - an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03745651?term=NCT03745651&draw=2&rank=1. NLM identifier: NCT03745651. Accessed 814, 2020.
   Google Scholar
• Pharma LEO. Delgocitinib cream for the treatment of moderate to severe atopic dermatitis during 8 weeks in adults, adolescents, and children. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03826901?term=NCT03826901&draw=2&rank=1. NLM identifier: NCT03826901 Accessed 814, 2020.
   Google Scholar
• Arcutis Biotherapeutics, Inc. Pharmacokinetics, safety, and efficacy of ARQ-151 once a day in adolescents and children with mild to moderate eczema. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04156191?term=NCT04156191&draw=2&rank=1. NLM identifier: NCT04156191 Accessed 814, 2020.
   Google Scholar
• Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89–98.e3. doi:10.1016/j.jaad.2018.06.04730554600
   PubMed Web of Science ®Google Scholar
• Pharma LEO. Tralokinumab monotherapy for adolescent subjects with moderate to severe atopic dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03526861?term=NCT03526861&draw=2&rank=1. NLM identifier: NCT03526861 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. Long-term safety and efficacy study of lebrikizumab (ly3650150) in participants with moderate-to-severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04392154?term=NCT04392154&draw=2&rank=1. NLM identifier: NCT04392154 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. Study to assess the safety and efficacy of lebrikizumab (ly3650150) in adolescent patients with moderate-to-severe atopic dermatitis (ADore). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04250350?term=NCT04250350&draw=2&rank=1. NLM identifier: NCT04250350 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. Evaluation of the efficacy and safety of lebrikizumab (ly3650150) in moderate to severe atopic dermatitis (advocate2). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04178967?term=NCT04178967&draw=2&rank=1. NLM identifier: NCT04178967 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. Evaluation of the efficacy and safety of lebrikizumab (ly3650150) in moderate to severe atopic dermatitis (advocate1). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04146363?term=NCT04146363&draw=2&rank=1. NLM identifier: NCT04146363 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. Safety and efficacy of lebrikizumab (ly3650150) in combination with topical corticosteroid in moderate to severe atopic dermatitis. (adhere). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04250337?term=NCT04250337&draw=2&rank=1. NLM identifier: NCT04250337 Accessed 814, 2020.
   Google Scholar
• Galderma R&D. A pharmacokinetics and safety study of nemolizumab in adolescent subjects with atopic dermatitis (AD). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03921411?term=NCT03921411&draw=1&rank=1. NLM identifier: NCT03921411 Accessed 814, 2020.
   Google Scholar
• Galderma R&D. Long-term safety and efficacy of nemolizumab with moderate-to-severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03989206?term=NCT03989206&draw=2&rank=1. NLM identifier: NCT03989206 Accessed 814, 2020.
   Google Scholar
• Galderma R&D. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03985943?term=NCT03985943&draw=2&rank=1. NLM identifier: NCT03985943 Accessed 814, 2020.
   Google Scholar
• Galderma R&D. Efficacy & safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03989349?term=NCT03989349&draw=2&rank=1. NLM identifier: NCT03989349 Accessed 814, 2020.
   Google Scholar
• Eli Lilly and Company. A study of baricitinib (ly3009104) in children and adolescents with atopic dermatitis (BREEZE-AD-PEDS), Available from: https://www.clinicaltrials.gov/ct2/show/NCT03952559?term=NCT03952559&draw=2&rank=1. NLM identifier: NCT03952559 Accessed 814, 2020.
   Google Scholar
• AbbVie. Evaluation of upadacitinib in adolescent and adult patients with moderate to severe atopic dermatitis (eczema) (measure up 1). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03569293?term=NCT03569293&draw=2&rank=1. NLM identifier: NCT03569293 Accessed 814, 2020.
   Google Scholar
• AbbVie. A study to evaluate upadacitinib in combination with topical corticosteroids in adolescent and adult participants with moderate to severe atopic dermatitis (AD Up). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03568318?term=NCT03568318&draw=2&rank=1. NLM identifier: NCT03568318 Accessed 814, 2020.
   Google Scholar
• AbbVie. A study to evaluate safety of upadacitinib in combination with topical corticosteroids in adolescent and adult participants with moderate to severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03661138?term=NCT03661138&draw=2&rank=1. NLM identifier: NCT03661138 Accessed 814, 2020.
   Google Scholar
• AbbVie. A study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis (measure up 2). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03607422?term=NCT03607422&draw=2&rank=1. NLM identifier: NCT03607422 Accessed 814, 2020.
   Google Scholar
• AbbVie. A study to evaluate the pharmacokinetics, safety and tolerability of upadacitinib in pediatric participants with severe atopic dermatitis. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03646604?term=NCT03646604&draw=2&rank=1. NLM identifier: NCT03646604 Accessed 814, 2020.
   Google Scholar
• Pfizer. Study to evaluate efficacy and safety of pf-04965842 with or without topical medications in subjects aged 12 years and older with moderate to severe atopic dermatitis (JADE EXTEND). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03422822?term=NCT03422822&draw=2&rank=1. NLM identifier: NCT03422822 Accessed 814, 2020.
   Google Scholar